Keenova Highlights Updated XIAFLEX Data for Peyronie’s Disease at AUA 2026
DUBLIN, May 15, 2026 Keenova Therapeutics announced updated clinical findings on XIAFLEX® (collagenase clostridium histolyticum) for the treatment of...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
DUBLIN, May 15, 2026 Keenova Therapeutics announced updated clinical findings on XIAFLEX® (collagenase clostridium histolyticum) for the treatment of...
LATHAM, N.Y., May 13, 2026 AngioDynamics announced new two-year data from the pivotal PRESERVE clinical trial, demonstrating that its...
SAN JOSE, Calif., May 14, 2026 Resurge Therapeutics announced positive clinical findings from two studies evaluating its proprietary IntraProstatic...
CULVER CITY, Calif. – May 5, 2026 ImmunityBio Inc. has announced it will present new comparative clinical data and...
